VET Cell Techsp. z o.o.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2023-03-21
Share capital
63 250,00 PLN
Activity description

Vet Cell Tech is a veterinary biotech company from Poland that develops innovative stem cell-based therapies for dogs and cats. They utilize a proprietary stem cell technology platform to create effective treatments for common diseases in companion animals. The company focuses on ensuring high safety profiles and cost-effectiveness in their products.

Registered address
ul. Profesora Michała Bobrzyńskiego 14, 30-348 Kraków, Poland
Website
vetcelltech.comWebsite active
Email
Email address current
Phone
Electronic delivery address
AE:PL-87122-26961-BBEAS-19

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 483.44kMedianUSD 126.89kAverageUSD 4.67m
Net profit
This companyUSD -519.51kMedianUSD -19.64AverageUSD 371.62k
Operating costs
This companyUSD 1.00mMedianUSD 165.83kAverageUSD 4.01m
Assets
This companyUSD 2.10mMedianUSD 251.40kAverageUSD 7.40m

Bank accounts

Registered as a VAT taxpayer on 2023-04-12. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

7 public aid cases recorded, with a total value of $2,177,505.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$55,240
De minimis aid (in accordance with Commission Regulation 2023/2831)
$52,722
Regional investment aid
$461.6K

European Funds

ProjectEU co-financing
Badania nad zastosowaniem terapii komórkowej w leczeniu dysfunkcji układu moczowego u zwierząt towarzyszących (suki)
$52,722
Opracowanie globalnie innowacyjnego leku weterynaryjnego na przewlekłe zapalenie nerek u kotów, opartego o allogeniczne komórki macierzyste oraz wdrożenie produkcji w warunkach standardu farmaceutycznego GMP
$1.6M
Zakup infrastruktury do prowadzenia prac B+R nad hodowlami komórkowymi w warunkach sterylnych w celu opracowania globalnie innowacyjnych weterynaryjnych terapii komórkowych
$468.5K

Tenders

No recorded participation in tenders.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Authorized Representatives

Konrad Grzegorz Szczukiewicz — Management Board Member
Marcin Krzysztof Liwoch — Management Board Member
Marcin Marek Majka — President of the Management Board

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Supervisory board

Artur Zaręba — Supervisory Board Member
Igor Rozbicki — Supervisory Board Member
Radosław Janus — Supervisory Board Member
Jolanta Kołodziejczyk — Supervisory Board Member
Karolina Kozłowska — Supervisory Board Member

Ownership

OwnerSharesShare valueStake
Marcin Krzysztof Liwoch (53)
168$2,269.0413.2806%
Marcin Marek Majka (54)
550$7,428.4243.4783%
Konrad Grzegorz Szczukiewicz (37)
163$2,201.5112.8854%
Piotr Antoni Sznelewski (57)
153$2,066.4512.0949%
Others
231$3,119.9418.2608%

Beneficial owners

Person
Marcin Krzysztof Liwoch (53)
Marcin Marek Majka (54)
Konrad Grzegorz Szczukiewicz (37)
Piotr Antoni Sznelewski (57)

Competitors

Change history

DateEvent
2025-08-05Share capital change
2025-08-05PKD change
2023-09-01Share capital change
2023-03-21Entered in the register

FAQ

Last updated: 2026-07-16